Product Description
A lipid-permeable tacrolimus analogue with homodimerizing activity. Rimiducid homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val) so that AP1903 binds to wild-type FKBP12 with 1000-fold lower affinity. This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered receptors such as the iCD40 receptor of the autologous dendritic cell vaccine BP-GMAX-CD1, resulting in receptor activation. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rimiducid)
Mechanisms of Action: Tacrolimus Analogue
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bellicum
Company Location: HOUSTON TX 77098
Company CEO: Richard A. Fair
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Italy, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Anemia, Aplastic|Fanconi Anemia|Fanconi Syndrome|Hemoglobinopathies|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Osteopetrosis
Phase 1: Breast Cancer|Colorectal Cancer|Graft vs Host Disease|Leukemia|Lymphoma|Multiple Myeloma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TROPIKANA | P1 |
Recruiting |
Small Cell Lung Cancer|Breast Cancer|Non-Small-Cell Lung Cancer |
2038-04-30 |
|
| P-BCMA-101-002 | P1 |
Active, not recruiting |
Multiple Myeloma |
2032-08-01 |
27% |
| CaspaCide TCR αβ haplo HSCT | P2 |
Active, not recruiting |
Hemoglobinopathies|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Fanconi Syndrome|Fanconi Anemia|Osteopetrosis|Anemia, Aplastic |
2032-01-18 |
|
| NCI-2024-03107 | P1 |
Recruiting |
Colorectal Cancer |
2029-01-18 |